Valeant, Kaken sign license deal to develop new chemical entity for psoriasis

This article was originally published here

Valeant Pharmaceuticals International’s subsidiary and Kaken Pharmaceutical have entered into a license agreement to develop and commercialize products featuring KP-470, an investigational compound for the topical treatment of psoriasis.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply